3D cell culture models in research: applications to lung cancer pharmacology

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 23, 2024

Lung cancer remains one of the leading causes cancer-related mortality worldwide, necessitating innovative research methodologies to improve treatment outcomes and develop novel strategies. The advent three-dimensional (3D) cell cultures has marked a significant advancement in lung research, offering more physiologically relevant model compared traditional two-dimensional (2D) cultures. This review elucidates various types 3D culture models currently used pharmacology, including spheroids, organoids engineered tissue models, having pivotal roles enhancing our understanding biology, facilitating drug development, advancing precision medicine. systems mimic complex spatial architecture microenvironment tumours, providing critical insights into cellular molecular mechanisms tumour progression, metastasis responses. Spheroids, derived from commercialized lines, effectively (TME), formation hypoxic nutrient gradients, crucial for evaluating penetration efficacy anti-cancer therapeutics. Organoids tumouroids, primary tissues, recapitulate heterogeneity cancers are instrumental personalized medicine approaches, supporting simulation vivo pharmacological responses patient-specific context. Moreover, these have been co-cultured with biomimicry extracellular matrix (ECM) components further heterotypic cell-cell cell-ECM interactions present within TME. significantly contributing identification therapeutic targets resistance against conventional therapies. Therefore, this summarizes latest findings involving together common laboratory-based assays study effects. Additionally, integration development workflows is discussed. accelerating translation laboratory clinical applications, thereby landscape treatment. By closely mirroring human not only enhance disease but also pave way effective

Language: Английский

---

UBASH3B-mediated MRPL12 Y60 dephosphorylation inhibits LUAD development by driving mitochondrial metabolism reprogramming

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Sept. 30, 2024

Language: Английский

---

Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement

American Journal of Respiratory and Critical Care Medicine, Journal Year: 2024, Volume and Issue: 210(5), P. 548 - 571

Published: Sept. 1, 2024

Despite significant advances in precision treatments and immunotherapy, lung cancer is the most common cause of death worldwide. To reduce incidence improve survival rates, a deeper understanding premalignancy multistep process tumorigenesis essential, allowing timely effective intervention before development.

Language: Английский

---

Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis

Nutrition and Cancer, Journal Year: 2024, Volume and Issue: 77(2), P. 299 - 310

Published: Oct. 20, 2024

Isoquercitrin possesses anti-tumor activity in several types of cancers, however, its effects and underlying mechanisms on lung cancer have not been reported. Human cell lines as well normal epithelial BEAS-2B cells were treated with isoquercitrin. The influences isoquercitrin

Language: Английский

---

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation

Translational Lung Cancer Research, Journal Year: 2024, Volume and Issue: 13(10), P. 2698 - 2712

Published: Oct. 1, 2024

Lung cancer is one of the most common malignant tumors worldwide. Despite advances in lung treatment, patients still face challenges related to drug resistance and recurrence. Current methods for evaluating anti-cancer activity are insufficient, as they rely on two-dimensional (2D) cell culture animal models. Therefore, development an

Language: Английский

---

[Development of a new platform for testing antiviral drugs using coronavirus-infected human nasal mucosa organoids].

PubMed, Journal Year: 2024, Volume and Issue: 44(11), P. 2227 - 2234

Published: Nov. 20, 2024

To establish a coronavirus (CoV) infection model using human nasal mucosa organoids for testing antiviral drugs and evaluate the feasibility of with viral as platforms research drug development.

Language: Английский

---

Establishment and Application of a Model for SARS-CoV-2 Infection of Human Nasal Mucosa Organoid

Jundishapur Journal of Microbiology, Journal Year: 2024, Volume and Issue: 17(10)

Published: Oct. 29, 2024

Background: The COVID-19 pandemic underscores the need for effective models to study SARS-CoV-2 infection and evaluate antiviral therapies. Objectives: This aimed develop a human nasal organoid model assess susceptibility its variants effects of compounds such as camostat, remdesivir, bergamottin. Methods: Nasal organoids were infected with HCoV-OC43 pseudoviruses, followed by wild-type variant strains in BSL-3 laboratory. Viral content was measured at 2, 24, 48 hours post-infection using qPCR, cells identified via immunofluorescence. Results: demonstrated pseudoviruses (P < 0.001) effectively variants. Remdesivir, hesperidin, bergamottin exhibited dose-dependent 0.0001). Conclusions: Human represent valuable studying evaluating drugs, particularly applications vitro.

Language: Английский

---